Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
about
Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemicEfficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trialsDaptomycin in paediatrics: current knowledge and the need for future researchEvaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection.A case of daptomycin-induced immune thrombocytopenia.Daptomycin in experimental murine pneumococcal meningitis.Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients.Influence of First-Line Antibiotics on the Antibacterial Activities of Acetone Stem Bark Extract of Acacia mearnsii De Wild. against Drug-Resistant Bacterial Isolates.National athletic trainers' association position statement: skin diseases.Identification of a novel clone, ST736, among Enterococcus faecium clinical isolates and its association with daptomycin nonsusceptibility.Molecular typing and phenotype characterization of methicillin-resistant Staphylococcus aureus isolates from blood in TaiwanAttenuation of cognitive impairment by the nonbacteriolytic antibiotic daptomycin in Wistar rats submitted to pneumococcal meningitis.Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis.Singly modified amikacin and tobramycin derivatives show increased rRNA A-site binding and higher potency against resistant bacteria.Prospective, open-label investigation of the pharmacokinetics of daptomycin during cardiopulmonary bypass surgery.In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains.Current strategies for the prevention and management of central line-associated bloodstream infections.Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteersSerum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus speciesIn vitro activities of daptomycin-, vancomycin-, and teicoplanin-loaded polymethylmethacrylate against methicillin-susceptible, methicillin-resistant, and vancomycin-intermediate strains of Staphylococcus aureus.Enterococcal endocarditis: can we win the war?Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections.Treatment and prevention of enterococcal infections--alternative and experimental approaches.MRSA: status and prospects for therapy? An evaluation of key papers on the topic of MRSA and antibiotic resistance.MRSA--what is it, and how do we deal with the problem?Epidemiology and treatment of community-associated methicillin-resistant Staphylococcus aureus in children.Pharmacoeconomics of treatment with the newer anti-Gram-positive agents.Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia.Mechanisms of resistance to daptomycin in Enterococcus faecium.Update on daptomycin: the first approved lipopeptide antibiotic.Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: the potential role of daptomycin.Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin?Genotyping of Methicillin Resistant Staphylococcus aureus from Tertiary Care Hospitals in Coimbatore, South India.Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era.Antimicrobial treatment for intra-abdominal infections.Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.Prescribing trends with daptomycin (cubicin) for the treatment of gram-positive infectionsSystematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections.Antimicrobial-resistant Streptococcus pneumoniae: trends and management.
P2860
Q24614464-BE13403D-4704-40B3-9FE9-4B30D4DD3FD6Q27000445-5B983B36-41F8-46C7-9CCB-05091AC6B7F6Q27006038-E8162DA6-23F3-4EE2-965F-604FA9F23E5FQ33239640-56B19A6F-6244-46A3-9610-615AFE374C68Q33403616-3D191D5A-DE3B-4CED-8790-B0AA39F39D0AQ33437256-99987F9D-C3FA-45BB-B990-96F5728AB9E8Q33518268-B889A95F-8D1A-4AB8-A489-7FA6D3A7411DQ33914695-EA9651CF-CB28-49EB-B668-74C956F2E311Q33984713-35EFA276-5DD5-48F3-B598-390974925430Q34058360-5428AC81-FFAB-49A3-BE0B-CDF1477D4F4FQ34146036-AD4AD006-53D0-49D0-AC54-962776E771EDQ34645552-7B4E67DC-4BE5-44E1-A04D-63248494F7F7Q34926950-BB1C1961-1F32-4266-B85F-9F5C3D0FE1B1Q34982853-A62D4F65-69A4-4D15-824D-398CD9F0C43AQ35004882-562C6FFE-0E07-4A99-B34E-121F9FE489E4Q35023234-9DF1D64B-DC9A-4487-A2E3-7523800DDD97Q35026591-6863CDE0-8DDF-46FC-AC7E-A55F9BF3E59DQ35091557-53FFAD2C-8181-470A-978C-D4F2B10502D3Q35127818-8A44CCED-0D2A-4149-8AD1-39B32BC2B2CDQ35598497-B232C1D8-879F-428B-9094-439B10D8039CQ35610638-1BA2FF18-4EA2-4865-8057-8E292433CCA7Q35782816-068E0AB2-777F-4EC8-8264-5355DF6DBB3CQ35871928-9B6007EF-223E-4B0B-B53F-8F14839124DAQ35873796-C970456E-6A31-478D-985F-74C2B4B1A231Q35976330-F95CA35D-2227-4ECD-971E-68CEBEE4C453Q36150828-A27E539E-887C-490E-B22E-8D83CA2BC596Q36379346-5AFFA807-CE44-4B68-B208-7BF576898CBFQ36458452-3A6EDCB4-DF34-46DB-A0B9-3F3AAC88AA4BQ36482313-9EE1E746-A237-4FEC-8CC5-D65BCE6EA263Q36482920-642052AB-10B7-4EB8-9C5D-7D0F535B5200Q36521880-D6CAC359-C1BA-450E-8F02-6099048AE1E0Q36642946-99021536-30E2-40B9-934D-373C2D99E3F3Q36839693-27D8F065-B8AE-4337-B8D3-1AAF3CEB970AQ36934554-EF88FCB4-1D37-4A29-BEAF-76DDFBC83A6BQ36967265-E9B20B06-3388-4BFF-A7E4-4252F757398FQ37000729-FCCD71FE-4710-462F-B7B7-C6D285784C7EQ37023118-71EAE04E-D168-43B2-9C04-321FBCF4848CQ37195896-16FB17F6-ED62-4ECB-BB5B-2C7AE7B0BA5FQ37263709-9271C2BA-5643-4FA9-9F50-393B23142F09Q37291341-6416650A-4E5A-435D-B25D-CB6E76F3E87D
P2860
Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Daptomycin: another novel agen ...... stant gram-positive pathogens.
@ast
Daptomycin: another novel agen ...... stant gram-positive pathogens.
@en
type
label
Daptomycin: another novel agen ...... stant gram-positive pathogens.
@ast
Daptomycin: another novel agen ...... stant gram-positive pathogens.
@en
prefLabel
Daptomycin: another novel agen ...... stant gram-positive pathogens.
@ast
Daptomycin: another novel agen ...... stant gram-positive pathogens.
@en
P2860
P356
P1476
Daptomycin: another novel agen ...... stant gram-positive pathogens.
@en
P2093
Christopher F Carpenter
Henry F Chambers
P2860
P304
P356
10.1086/383472
P407
P577
2004-03-11T00:00:00Z